Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. Mai 2024 17:00 ET | Quelle: Tizona Therapeutics Inc

Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024

TTX-080 plus EGFR Inhibitor Cetuximab Demonstrated Promising Evidence of Clinical Activity in Patients with Biomarker-Defined Metastatic Colorectal Cancer and Locally Advanced/Metastatic Head and Neck...
15. September 2020 09:00 ET | Quelle: Tizona Therapeutics Inc

Tizona Appoints Christine O’Brien as Chief Executive Officer

-- Transaction with Gilead Sciences Closed -- -- Tizona Advances TTX-080, a Novel Anti-HLA-G Antibody, with First Patients Treated in Phase I Study – SOUTH SAN FRANCISCO, Calif., Sept. 15, 2020 ...
19. Februar 2020 09:00 ET | Quelle: Tizona Therapeutics Inc

Tizona to Present at The Cowen and Company 40th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a clinical stage, privately held company developing first-in-class cancer immunotherapies, announced today...
15. Mai 2019 16:00 ET | Quelle: Tizona Therapeutics Inc

Tizona Elects Daniel K. Spiegelman to Its Board of Directors

SOUTH SAN FRANCISCO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a privately held immunotherapy company, today announced the appointment of Daniel K. Spiegelman to its Board...